The Celiac Disease Foundation was proud to be a sponsor of the MedAboutData Hackathon in Haifa, Israel. During the hackathon, the ‘CeliACT’ team presented an innovative product that can assist in early detection of celiac disease.

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!

Researchers analyzed iCureCeliac® patient registry data to determine the effect of celiac disease-related depression on patients’ symptomatic response to a gluten-free diet.

Attention: Volunteers who have prior confirmation of celiac disease from blood work or a biopsy. If you meet the following criteria, you may qualify for a clinical research study of an investigational drug. Medical insurance is not necessary.

The CeliacShield Study is being conducted to assess the investigational drug latiglutenase and its ability to protect the small intestine of celiac disease patients from gluten exposure.

Results from a new study suggest that cell immunity in the bowel is irreversibly altered by celiac disease. Early diagnosis and treatment of celiac disease may be able to save some of these beneficial cells and prevent additional permanent damage.

Increased consumption of a bacterial enzyme that is a common additive in processed foods might be related to the increased incidence of celiac disease.

The Celiac Disease Foundation Young Investigator Research Grant Award is a one- to three-year grant totaling up to $180,000. The purpose of the Award is to encourage exceptional investigators to pursue independent careers in celiac disease research.

If you're interested in advancing treatments for cross-contact, and you meet the qualifications below, you may be able to participate in a study located in Seattle, Washington and Dallas, Texas.

ImmusanT, Inc., has announced that its therapeutic vaccine candidate, Nexvax2, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).